The SMN2 gene acts as a backup for the SMN1 gene by making some of the SMN protein, which nerve cells need to control muscles. If too little working SMN protein is available, people can develop muscle weakness and movement problems seen in spinal muscular atrophy. This gene plays an important role in how severe SMA may be, because having more SMN2 copies often means the body can make more backup protein. SMN2 is best known in discussions of newborn screening and SMA treatment.
What is a gene?
A gene is a stretch of DNA that carries instructions your cells use to make molecules or regulate processes in the body. Some genes provide the information needed to produce proteins, the working parts of cells. Others mainly help control when certain processes happen, where they take place, and how strongly they operate. Together, genes affect how the body develops and works, and they can also shape how you respond to food, stress, or medications. To explore this topic in more detail, you can learn more in the LearnHub.
Overview
SMN2Gene function
What if the gene works
Your cells use the SMN2 gene to make a small amount of SMN protein. This protein helps motor nerve cells stay healthy and supports the signals that control muscle movement.
Risk
What if the gene does not work
When the SMN2 gene provides too little SMN protein, spinal muscular atrophy can start earlier and cause more weakness plus breathing or feeding problems. Milder and more severe variants, or fewer SMN2 copies, can change how much the gene helps.
Treatment
What does that mean for your treatment
A loss-of-function change or very low copy number in the SMN2 gene usually means less backup SMN protein, so treatment is started as early as possible. Nusinersen and risdiplam help the body make more SMN protein from SMN2, so SMN2 status can shape urgency and expected benefit. Onasemnogene abeparvovec replaces SMN1 and does not depend on SMN2.
Conditions associated with SMN2
Gene function
What if the gene works
Your cells use the SMN2 gene to make extra survival motor neuron (SMN) protein, which supports everyday cell activity. This protein is used in many tissues and is especially important in motor neurons, the nerve cells that help muscles move. Understanding how the SMN2 gene works can make it easier to see how cells process genetic messages and stay organized.
The SMN2 gene adds to your body’s supply of SMN protein. That extra supply is part of what the SMN2 gene does in the body to support routine cell function, especially in motor neurons.
SMN protein helps build small cell helpers that process RNA, the working copy of genetic instructions. This lets cells prepare protein making messages in an orderly way before they are used.
SMN protein helps organize RNA and proteins into working groups inside cells. This supports their movement to the right place at the right time for normal cell activity.
What is a variant?
A genetic variant is a minor change in a gene’s DNA sequence. These changes are common and are part of normal human diversity, including differences in appearance, metabolism, and the way the body responds to environmental influences. Many variants do not cause any noticeable effect and simply represent natural genetic variation. In some cases, though, a variant can change how a gene works more significantly and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Many SMN2 gene variants change how the cell processes its RNA message, especially whether exon 7, one small coding segment, is kept or skipped. This alters how much full length, stable SMN protein is produced. Milder variants, including extra SMN2 copies or changes that improve exon 7 inclusion, can raise protein output, while more severe variants can lower it further. This helps explain how SMN2 gene variants affect spinal muscular atrophy severity and when symptoms may begin.
How variants are linked to conditions
Changes involving the SMN2 gene are mainly linked to spinal muscular atrophy, where SMN2 gene copy number helps shape how symptoms appear. In general, more SMN2 copies are associated with a milder course, while fewer copies are linked to earlier onset and greater muscle weakness. Some rare SMN2 variants can also modify severity. On their own, common SMN2 differences do not diagnose the condition.
A variant is not necessarily a diagnosis
Genetic variants are a usual part of human biology and are widely seen in the general population. Most do not have a direct effect on health and simply contribute to normal human diversity. For many genes, carrying a variant associated with a condition points to a possible link rather than a certain diagnosis, especially when multiple genes and environmental factors also play a role. In some situations, though, a single well characterized variant in a specific gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For spinal muscular atrophy, SMN2 mainly changes how severe the condition may be rather than whether it happens at all, which is mostly linked to the SMN1 gene. In general, more copies of SMN2 are linked with milder symptoms, while fewer copies are often linked with earlier and more serious muscle weakness.
Inheritance of SMN2 variants
There is not a single, broadly confirmed disease inheritance pattern for SMN2 gene variants on their own, because SMN2 most often acts as a modifier of spinal muscular atrophy rather than the main cause. In practice, SMN2 gene inheritance follows the usual pattern for genes on chromosome 5: it sits on an autosome, so you inherit one copy from each parent. This means changes in SMN2 can be passed from either parent to a child, but their effect depends heavily on the broader genetic context, especially nearby changes involving the SMN1 gene.
What does my SMN2 result mean for my family?
There is not a broadly confirmed, condition-specific family inheritance pattern for SMN2 on its own. In practice, SMN2 usually helps modify how spinal muscular atrophy shows up rather than acting as the main cause, so what it means for relatives depends on the full genetic result, especially the SMN1 finding.
Genetic information
Genetic testing
How you find out about variants
SMN2 genetic testing usually uses a blood or saliva sample. The lab measures how many copies of the SMN2 gene you have and, when needed, looks for variants in the gene’s spelling. This information can help clarify results after spinal muscular atrophy testing.
When should I consider getting a genetic test?
SMN2 testing is usually considered when spinal muscular atrophy (SMA), a genetic condition that causes muscle weakness, is suspected or already confirmed. It can help show how severe SMA may be and support treatment planning, especially for babies found through newborn screening or when SMA runs in the family.
A genetic result is only one part of your health story
Genetic results can provide useful insight, but how much they explain depends on the condition and the kind of variant involved. How the body functions over time is also shaped by many factors, including lifestyle, environment, age, and medical history. In some conditions, especially those influenced by many genes, genetic information offers context rather than certainty and is most helpful when considered alongside other parts of care. In other situations, a genetic result may offer a clear answer. In areas like medication response, genetic results can also help put individual experiences into perspective.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. This helps explain why the same treatment works well for one person, works less well for another, or causes more side effects in someone else. Part of the reason is that inherited differences can change how the body breaks down, moves, or responds to a drug. These differences are common and can influence both how effective a medicine feels and how sensitive a person may be to it.
What is Pharmacogenetics?
Pharmacogenetics examines how genetic differences can affect the way medications work. It focuses on links between genes and drugs to help explain why the same treatment may work differently from one person to another. For many medicines, genes can influence both how strongly a drug works and how the body processes it. This information can support more informed and more individualized treatment decisions. To explore this subject in greater detail, you can learn more in the LearnHub.
Drugs influenced by the SMN2 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding how most medicines are chosen or adjusted, so general concerns about symptoms, treatment effects, or side effects are best discussed with your doctor. SMN2 is mainly used in spinal muscular atrophy to help understand the condition and, in some studies, to look at how people respond to SMA treatments.
History
The history of the SMN2 gene is closely tied to efforts to understand spinal muscular atrophy, a condition long recognized through its inherited pattern. In the 1990s, researchers studying chromosome 5 identified two very similar genes, SMN1 and the SMN2 gene, which marked an important step in human genetics. Initially understood only through visible traits, later recognized as tied to a specific gene, spinal muscular atrophy became one of the clearest examples of how a second gene can shape disease severity. Building on this early work, scientists uncovered more about the SMN2 gene and why copy number became such an important part of testing and prognosis. That discovery helped reshape newborn screening and later guided the development of targeted therapies.